Basecamp Wealth Advisors’s Immunovant IMVT Stock Holding History

Basecamp Wealth Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-31	Closed	-$788	–	2101
2025 Q4	$788	Buy	+31	New	+$691	﹤0.01%	1544

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Basecamp Wealth Advisors's IMVT Position: Q1 2026 in Review

Basecamp Wealth Advisors sold out of Immunovant (IMVT) in Q1 2026, closing a stake of 31 shares — an estimated $788 sold.

Basecamp Wealth Advisors first reported a position in IMVT in Q4 2025 and held it in 1 quarter. The position peaked at $788 in Q4 2025. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

Basecamp Wealth Advisors reported no remaining Immunovant position as of Q1 2026 after selling out during the quarter.
Basecamp Wealth Advisors sold 31 Immunovant shares in Q1 2026, an estimated $788.
Basecamp Wealth Advisors first reported a position in Immunovant in Q4 2025 and held it in 1 quarter.
Basecamp Wealth Advisors's Immunovant position peaked at $788 in Q4 2025.
215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q1 2026, filed 24 Jun 2026.